10.17.13
Roche
YTD Revenues: 34.9 billion CHF (+3%)
Comments: Pharmaceutical sales were 27.2 billion CHF, up 4% driven by cancer drugs Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra. The HER2 breast-cancer franchise, which includes Herceptin, Perjeta and Kadcyla, grew 13%. Avastin sales rose 13% due to recent approvals in ovarian cancer in Europe, colorectal cancer in the U.S. and Europe, and the first approval for newly diagnosed glioblastoma in Japan. Sales in the U.S. were up 11% to 11.4 billion. Sales in Europe were up 4% to 7.0 billion. Sales in Japan were down 16% to 2.5 billion. Diagnostics Division sales were 7.7 billion, up 2%. All numbers are in CHF.
YTD Revenues: 34.9 billion CHF (+3%)
Comments: Pharmaceutical sales were 27.2 billion CHF, up 4% driven by cancer drugs Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra. The HER2 breast-cancer franchise, which includes Herceptin, Perjeta and Kadcyla, grew 13%. Avastin sales rose 13% due to recent approvals in ovarian cancer in Europe, colorectal cancer in the U.S. and Europe, and the first approval for newly diagnosed glioblastoma in Japan. Sales in the U.S. were up 11% to 11.4 billion. Sales in Europe were up 4% to 7.0 billion. Sales in Japan were down 16% to 2.5 billion. Diagnostics Division sales were 7.7 billion, up 2%. All numbers are in CHF.
